Difference between revisions of "Idarucizumab (Praxbind)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= A monoclonal antibody fragment that binds Dabigatran (Pradaxa) with very high affinity. In clinical trials it completely reverses the effect of dabig...") |
m (PeterYang moved page Idarucizumab to Idarucizumab (Praxbind): FDA approval) |
(No difference)
| |
Revision as of 05:47, 19 October 2015
Mechanism of action
A monoclonal antibody fragment that binds Dabigatran (Pradaxa) with very high affinity. In clinical trials it completely reverses the effect of dabigatran within minutes.
Preliminary data
- Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015 Aug 6;373(6):511-520. Epub 2015 Jun 22. link to original article PubMed